Detalles de la búsqueda
1.
Embracing model-based designs for dose-finding trials.
Br J Cancer
; 117(3): 332-339, 2017 Jul 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-28664918
2.
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
Lancet Oncol
; 15(2): 143-55, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24411639
3.
How is retrospective independent review influenced by investigator-introduced informative censoring: a quantitative approach.
Stat Med
; 30(29): 3373-86, 2011 Dec 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-21953353
4.
A statistical model for the dependence between progression-free survival and overall survival.
Stat Med
; 28(21): 2669-86, 2009 Sep 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-19579225
5.
Change in non-small-cell lung cancer tumor size in patients treated with nintedanib plus docetaxel: analyses from the Phase III LUME-Lung 1 study.
Onco Targets Ther
; 11: 4573-4582, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30122949
6.
Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer.
ESMO Open
; 2(1): e000102, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28761724
7.
Comprehensive Biomarker Analyses in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer Prospectively Treated with the Polo-Like Kinase 1 Inhibitor BI2536.
Oncol Res Treat
; 40(7-8): 435-439, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28628916
8.
Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial.
Lung Cancer
; 102: 65-73, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27987591
9.
Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer.
Eur J Cancer
; 51(3): 317-26, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25534294
10.
Auditory stream segregation relying on timbre involves left auditory cortex.
Neuroreport
; 15(9): 1511-4, 2004 Jun 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-15194885
11.
A phase I open-label dose-escalation study of intravenous BI 2536 together with pemetrexed in previously treated patients with non-small-cell lung cancer.
Clin Lung Cancer
; 14(1): 19-27, 2013 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-22658814
12.
Anomalous Auditory Cortex Activations in Colored Hearing Synaesthetes: An fMRI-Study.
Seeing Perceiving
; 24(4): 391-405, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-21864461
13.
The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial.
J Thorac Oncol
; 5(7): 1060-7, 2010 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-20526206
14.
Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors.
Clin Cancer Res
; 16(1): 311-9, 2010 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-20028771
15.
An open-label dose-escalation study of BIBF 1120 in patients with relapsed or refractory multiple myeloma.
Anticancer Res
; 29(10): 4233-8, 2009 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-19846979
16.
Working memory specific activity in auditory cortex: potential correlates of sequential processing and maintenance.
Cereb Cortex
; 17(11): 2544-52, 2007 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-17204817
Resultados
1 -
16
de 16
1
Próxima >
>>